Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03652337 · ClinicalTrials.gov registry record · NA

Meibomian Gland Dysfunction Management

A NA study of Meibomian Gland Dysfunction and Contact Lens Discomfort, sponsored by University of the Incarnate Word.

Active
Registry status
NA
Development phase
60
Enrollment target
1
Study location

NCT03652337: Active NA study of Meibomian Gland Dysfunction and Contact Lens Discomfort, sponsored by University of the Incarnate Word.

NCT03652337 is a NA study of Meibomian Gland Dysfunction and Contact Lens Discomfort that is active but no longer recruiting, run by University of the Incarnate Word. The registered enrollment target is 60 participants, below the 95-participant average among 8 other Meibomian Gland Dysfunction trials with a reported enrollment target (37% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03652337, a NA study of Meibomian Gland Dysfunction and Contact Lens Discomfort, is active but no longer recruiting, sponsored by University of the Incarnate Word.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
60 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to compare electronic debridement of the eyelid margin (BlephEx) to manual debridement of the eyelid margin as treatment options for patients intolerant to contact lens wear consequent to Meibomian gland dysfunction.

Primary Outcome

Betterment of symptoms (improvement in contact lens discomfort) will be measured using two different surveys - Ocular Surface Disease Index (OSID) and Contact Lens Dry Eye Questionnaire-8 (CLDEQ-8). The OSDI scores can range from 0 to 100. The CLDEQ-8 scores can range from 0 to 37. In both the questionnaires, a lowering of the score during follow-up visits represents a betterment of symptoms suffered by the patient. The numerical change in the scores on these two questionnaires will be documente

Interventions

  • DEVICE BlephEx
  • DEVICE Manual debridement

Study Locations (1)

Texas

  • Rosenberg School of Optometry - San Antonio

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2018-05-10
Est. Completion 2019-04-10
Phase NA
University of the Incarnate Word

11 total trials

What the registry record for NCT03652337 still lists

NCT03652337 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 95-participant average among 8 other Meibomian Gland Dysfunction trials with a reported enrollment target (37% lower).

The record links to 2 conditions, with Meibomian Gland Dysfunction appearing as the primary indexed condition, and to 2 interventions - of which BlephEx is the first listed.

NCT03652337 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT03652337 about?

NCT03652337 is a clinical study titled "Meibomian Gland Dysfunction Management". The purpose of this study is to compare electronic debridement of the eyelid margin (BlephEx) to manual debridement of the eyelid margin as treatment options for patients intolerant to contact lens wear consequent to Meibomian gland dysfunction.

What is the current status of trial NCT03652337?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 60 participants. The study started on 2018-05-10. Estimated completion is 2019-04-10.

What conditions does trial NCT03652337 study?

This clinical trial studies the following conditions: Meibomian Gland Dysfunction, Contact Lens Discomfort.

What interventions are being tested in trial NCT03652337?

The interventions under investigation include: BlephEx (DEVICE), Manual debridement (DEVICE).

Who is sponsoring clinical trial NCT03652337?

This trial is sponsored by University of the Incarnate Word, which has 11 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03652337 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Meibomian Gland Dysfunction

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03652337's enrollment target sits among peer trials

60 6th of 8 higher than 3 of 8 other Meibomian Gland Dysfunction trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Meibomian Gland Dysfunction trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00576069 · 60 participants

    Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma

  • NCT01297400 · 60 participants · Phase 2

    Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns

  • NCT01734122 · 60 participants

    Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor

  • NCT01804634 · 60 participants · Phase 2

    Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03652337, the US trial registry maintained by the National Library of Medicine. NCT03652337 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.